文摘
摘要目的:评估脑microbleed之间的关系(CMB)负担和migraine-related残疾患者的大脑常染色体显性与皮层下梗死和脑白质病动脉病(CADASIL)。
背景:CADASIL突变造成的NOTCH3基因导致进行性中枢神经系统小血管疾病。患者往往共存偏头痛先兆(MA),虽然其底层CADASIL病理生理学的关系尚不清楚。
设计/方法:横断面,我们进行了前瞻性观察性研究的一系列成人CADASIL脑部MRI hemosiderin-sensitive序列。Microbleed解剖评定量表(火星)被用来量化招商银行负担的顺序推进分数意味着更大的招商银行数量。偏头痛残疾评估问卷(MIDAS)被用来量化偏头痛相关残疾(> 20 0 - 5、6 - 10 - 20日,意思不,最少,适度有限,分别和极其有限的残疾)。脑部核磁共振成像评估盲法临床数据或调查问卷的结果。
结果:23 CADASIL马,没有患者包括(入学年龄,59年;65%的女性)。总共有43.5%(10/23)有≥1大富翁(平均26岁,范围从0到197)和56.5%(13/23)有≥1招商银行(火星范围:0 - 53)。那些≥1 CMBs的可能性大大减少MIDAS≥1(奇数比0.05;95%可信区间0.01到0.49;P= 0.01)。逆关系仍然重要年龄调整后MRI扫描和MIDAS面试。
结论:独特的逆关系之间指出招商银行负担和migraine-related残疾CADASIL病人。未来的调查可能有助于理解马表现型的关系在CADASIL CMBs, trigeminovascular系统的影响对脑小血管疾病和新的治疗途径在CADASIL阻止小血管疾病进展。
披露:戈尔茨坦没有披露。巴迪博士没有披露。克洛斯博士没有披露。博士没有披露。霍奇博士没有披露。布朗医生没有披露。Dodick博士已经收到个人赔偿咨询、担任科学顾问委员会说,或其他活动从Acorda Dodick博士报告个人费用,安进,桤木,爱力根,自主技术,Biohaven, Colucid,礼来,eNeura,远见,Neurolief, Zosano,西城戈尔,韦丹塔Associates Promius制药,麦哲伦医疗、CC西福特集团Nocira,诺华,NuPathe, Supernus, Electrocore, Tonix, Teva, Alcobra, Insys,日常,查尔斯顿实验室Biocentric、Theranica,氙。ZP Opco。旅行费用报销和演讲费从太阳制药。预计未来3周内咨询收入不是之前报道:推动制药(目前正在审查由梅奥诊所医疗行业关系委员会)。 Compensation for activities related to data safety monitoring committee from Axsome. Speaking fees, or fees related to CME content development: Healthlogix, Medicom Worldwide, Medlogix Communications, MedNet, Miller Medical Communications, PeerView Operation Services America, Web MD/Medscape, American Academy of Neurology, American Headache Society, PeerView Institute for Medical Education, Chameleon Communications, Academy for Continued Healthcare Learning, Universal Meeting Management, Haymarket Medical Education, Global Scientific Communications, UpToDate, Meeting LogiX. Consulting use agreement through employer: NeuroAssessment Systems, Myndshft. Dr. Dodick has received compensation for serving on the Board of Directors of Board of Directors position: King-Devick Technologies, Ontologics. Dr. Dodick holds stock and/or stock options in Hold equity in: Aural Analytics, Healint, Theranica, Second Opinion/Mobile Health, Epien, which sponsored research in which Dr. Dodick was involved as an investigator. Dr. Dodick holds stock and/or stock options in Hold equity in: Aural Analytics, Healint, Theranica, Second Opinion/Mobile Health, and Epien. Dr. Rozen has nothing to disclose. Dr. Capobianco has nothing to disclose. Dr. Lin has nothing to disclose. Dr. Huang has nothing to disclose. Dr. Meschia has nothing to disclose.
